Research graph

References

References from Social Media Discussions of Anti-Diabetic Drugs and the Popularity of GLP-1 Therapies: Content Analysis. Local targets link to admitted publications; unresolved targets remain external evidence.

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google Trends analysis

10.1093/asj/sjad211 · External reference

Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity

10.1001/jamainternmed.2024.2525 · External reference

Prescription fills for semaglutide products by payment method

10.1001/jamahealthforum.2024.2026 · External reference

Public perspectives on anti-diabetic drugs: exploratory analysis of Twitter posts

10.2196/24681 · External reference

Unresolved reference

External reference

Spending on glucagon-like peptide-1 receptor agonists among US adults

10.1001/jamanetworkopen.2025.2964 · External reference

State-level variation in glucagon-like peptide-1 receptor agonists fills and spending by obesity prevalence, 2023

10.1161/jaha.125.043137 · External reference

Unresolved reference

External reference

The prevalence and consequences of support for off-label Ozempic prescriptions

10.1017/s1744133124000306 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Should I consider metformin therapy for weight loss in patients with obesity but without diabetes?

10.3949/ccjm.90a.22096 · External reference

Unresolved reference

External reference